Cytena and AstraZeneca collaborate to develop plate based microbioreactors for cell line development workflows

Cytena GmbH and its affiliate cytena Bioprocess Solutions Ltd., part of CELLINK Life Sciences, announced today that they will collaborate with AstraZeneca to develop a new generation of plate-based microbioreactors that can improve the efficiency of cell line development workflows. Cytena, which focuses on developing and commercializing innovative single-cell isolation and cultivation technologies, says that its collaboration with AstraZeneca will also explore machine learning algorithms for enhanced single-cell cloning. This collaboration will leverage Cytena’s recent technological advances in the field of single-cell isolation and bioprocessing to increase efficiency and shorten timelines in the discovery and production of therapeutic antibodies. Therapeutic antibodies are biopharmaceuticals widely used in the treatment of cancer, autoimmune and inflammatory diseases; they are also used for targeted drug delivery.

Cytena is a CELLINK company based in Freiburg, Germany, and Taipei, Taiwan.

For further information, please contact:

Erik Gatenholm, CEO                                                                                    Gusten Danielsson, CFO                             
Phone (Sweden): +46 73 267 00 00                                                                Phone (Sweden): +46 70 991 86 04      
Phone (US): +1 (650) 515 5566                                                                       Phone (US): +1 (857) 332 2138
Email: eg@cellink.com                                                                                     Email: gd@cellink.com                                

About CELLINK

CELLINK is a global life-science company providing technologies, products, and services to create, understand, and master cell and molecular biology, with a focus on three main application areas: bioprinting, analysis, and liquid handling & bioprocessing. The company develops and markets innovative cell culture technologies, enabling researchers in the life sciences to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016, CELLINK’s products have been adopted by researchers and scientists in more than 1,000 laboratories with more than 100 publication citations, the majority of the largest pharmaceutical companies and has been delivered to more than 55 countries around the world. The company’s vision is to create the future of medicine.

Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq Stockholm Main Market under CLNK B.